Hemophilia Gene Therapy: Expectations for Reliability and Accessibility

Hemophilia Gene Therapy: Expectations for Reliability and Accessibility

Listen to Andrew D. Leavitt, MD, Professor, Department of Laboratory Medicine and Medicine (Division of Hematology/Oncology), UCSF, discuss the expectations for reliability and accessibility of Hemophilia A, Hemophilia B, and Factor VIII and IX Gene Therapy. This podcast is part of the ISTH comprehensive educational resource designed by leading experts for the global hemophilia community to help keep you abreast on the evolving science and latest clinical advancements in gene therapy and hemophilia research.

Andrew D. Leavitt, MD, PhD
Andrew D. Leavitt, MD
Professor
Department of Laboratory Medicine and Medicine
University of California San Francisco
San Francisco, California

Andrew D. Leavitt, MD, attended Harvard Medical School, completed his internal medicine residency at the University of Michigan (Ann Arbor), and completed his hematology fellowship at the University of California, San Francisco (UCSF) where he has been on faculty since 1992. He is a Professor of Laboratory Medicine and Medicine (Hematology) at UCSF, where he directs the non-malignant hematology activities in the Division of Hematology/Oncology in the Department of Medicine and serves as the medical director for the Adult Hemophilia Treatment Center. His past basic research activities focused on megakaryocyte and platelet biology.

Image

Please enable the javascript to submit this form

Supported by educational grants from BioMarin, CSL Behring, Pfizer and Spark Therapeutics

Essential SSL